NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmRefractory Multiple MyelomaAdvanced LymphomaRefractory LymphomaHematopoietic and Lymphoid Cell NeoplasmRefractory Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439292
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
Phase 2
Withdrawn
- Conditions
- Refractory Plasma Cell MyelomaAdvanced Malignant Solid NeoplasmAdvanced LymphomaHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04439305
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory LymphomaHematopoietic and Lymphoid Cell NeoplasmRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439123
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaAdvanced LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT04439344
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory Multiple MyelomaAdvanced LymphomaRefractory LymphomaRefractory Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT04439318
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
Phase 2
Active, not recruiting
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmAdvanced LymphomaAdvanced Malignant Solid NeoplasmRefractory LymphomaRefractory Multiple MyelomaRefractory Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT04439253
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory Malignant Solid NeoplasmRefractory Multiple MyelomaAdvanced LymphomaRefractory Lymphoma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439188
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT04439331
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
Phase 2
Active, not recruiting
- Conditions
- Refractory Malignant Solid NeoplasmRefractory LymphomaAdvanced LymphomaHematopoietic and Lymphoid Cell NeoplasmRefractory Multiple MyelomaAdvanced Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT04439110
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
Phase 2
Completed
- Conditions
- Refractory LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory Plasma Cell MyelomaRefractory Malignant Solid NeoplasmAdvanced Lymphoma
- Interventions
- Drug: FGFR Inhibitor AZD4547
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT04439240
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath